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Adult and cord blood T cells can acquire HA-1
specificity through HA-1 T-cell receptor gene transfer
The minor histocompatibility anti-gen (mHag) HA-1 is a polymorphicantigen that is presented in the con-
text of HLA-A2.1 The tissue distribution of
HA-1 is restricted to hematopoietic cells
and carcinomas.2,3 It can, therefore, func-
tion as a tumor target antigen for stem cell
based immunotherapy of malignancies. In
the setting of  HLA-matched HA-1-mis-
matched stem cell transplantation (SCT)
for hematologic malignancies, T cells from
the HA-1neg stem cell donor can recognize
HA-1 expressed by the patient's leukemic
cells.4 In vivo and in vitro generation of
HLA-A2-restricted HA-1-specific cytotox-
ic T lymphocytes (CTL) has previously
been reported.5,6 T cells expressing the HA-
1-specific T-cell receptor (TCR) can be
monitored by staining peripheral blood
mononuclear cells with HLA-A2/HA-1
tetramers7 and by TCRBV spectratyping.8
Both in vitro and in vivo generated HA-1-
specific T-cell clones analyzed so far exclu-
sively use the TCR BV7S9 variable
domain in combination with different
TCR BD, BJ, TCRAV and AJ regions.8,9 The
CDR1 region of the TCRBV does not,
however, seem to play a major role in the
interaction with the HLA-A2/HA-1 lig-
and.10 
Donor lymphocyte infusion (DLI) with
HA-1- specific CTL generated from adult
or cord blood donor cells provides a feasi-
ble treatment for relapsed HLA-A2pos/HA-
1pos leukemia patients.6,11 Ex vivo CTL
induction and expansion for adoptive
immunotherapy is, however, time-con-
suming and not successful in all stem cell
donors. Gene transfer of the HLA-A2-
restricted HA-1-specific TCR into donor T
cells may provide an alternative treatment
strategy. Several studies have described
the transmission of various antigenic
specificities by TCR transfer.12-15 We earlier
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Background and Objectives. Minor histocompatibility antigen (mHag)-specific graft-ver-
sus-leukemia reactivities are observed following unselected donor lymphocyte infusion
for the treatment of relapse after HLA-matched mHag-mismatched stem cell transplan-
tation (SCT). Adoptive transfer of donor-derived ex vivo-generated HA-1-specific oligo-
clonal T cells or HA-1 peptide patient vaccination are currently being explored as cura-
tive tools for stem cell based immunotherapy of hematologic malignancies. Another
treatment modality to eradicate residual leukemic cells after SCT is the transfer of the
HA-1 hematopoietic-specific T-cell receptor (TCR) into cells from the stem cell donor.
This strategy would be particularly useful in case of relapse after cord blood transplan-
tation (CBT) and is explored in this study. 
Design and Methods. HLA-A2neg adult peripheral blood and cord blood mononuclear
cells were transduced with the genes encoding the HA-1a and b  TCR chains derived
from established HA-1 specific cytotoxic T lymphocyte clones. 
Results. The T cells transduced with HA-1 TCRab showed consistent marker gene
expression, but low staining with HLA-A2/HA-1 tetrameric complexes. They did, howev-
er, show hematopoietic-restricted cytolytic activity against HLA-A2pos/HA-1pos target cells,
including leukemic cells.
Interpretation and Conclusions. The low level of HA-1--specific tetramer staining of HA-
1 TCRab transduced T cells may be caused by hybrid TCR formation of the transferred
TCRa and b chains with endogenous TCRa and b chains. This may cause unwanted
alloreactivity and requires attention. The HA-1 TCRab transduced T cells show that the
HA-1 TCR can be functionally transferred into donor mononuclear cells, which can be
exploited in immunotherapeutic settings of SCT and CBT for hematologic malignan-
cies. 
Key  words: T cell receptor, gene transfer, minor histocompatibility antigen,
immunotherapy
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reported on successful gene transduction of the TCR
specific for the mHag HA-2 into peripheral T lym-
phocytes.16,17 Since the hematopoietic-specific HA-1
antigen is additionally expressed on a series of
epithelial carcinomas,3,18 we studied the feasibility of
HA-1 TCR gene transfer into peripheral blood cells
derived from adult or cord blood donors. We chose
to transfer the HA-1 TCR specificity into HLA-A2neg
donor T cells which enables usage of the HA-1-spe-
cific immunotherapy in HLA-mismatched SCT set-
tings. The HA-1 TCRa and b genes used for trans-
duction were derived from two established HA-1-
specific HLA-A2-restricted T-cell clones, 3HA15 and
5W38, previously isolated from different patients
after HLA-identical SCT.5 Both clones expressed the
same TCR BV7S9, but different TCR AV chains. The
individual genes encoding the a and b TCR chains of
both CTL clones were cloned into retroviral vectors
and the specificity and functionality of the TCR-
transduced adult and cord blood CD8+ T cells were
studied.
Design and Methods
Construction of retroviral vectors and generation of
retroviral supernatant
Total RNA from the mHag HA-1- specific HLA-A2-
restricted T cell clones 3HA15 and 5W38 was extract-
ed using Trizol (Gibco, Carlsbad, CA, USA). The
mRNA was reverse transcribed into single-strand
cDNA by reverse transcriptase using oligo dT
primers (Pharmacia, Uppsala, Sweden). Using
primers that cover the complete repertoire of known
TCR chains, TCRa and b, usage of the two clones
was determined. Both T cell clones expressed the
TCR BV7S9, as previously described.8,9 The 5W38 T-
cell clone expresses the TCR AV10S1; clone 3HA15
expresses two in-frame TCRa chains, TCR AV32 and
TCR AV3S1 (data not shown). Pilot experiments
revealed that TCR AV3S1, in combination with TCR
BV7S9, forms the functional HA-1-specific HLA-A2-
restricted TCR of CTL clone 3HA15. Two bicistronic
retroviral vectors based on the pLZRS backbone19
were used, containing an internal ribosome entry site
(IRES) and the marker gene enhanced green fluores-
cent protein (pLZRS-eGFP)20 or a truncated form of
the nerve growth factor receptor (pLZRS-dNGF-R).21
The individual genes encoding the a and b TCR
chains were amplified by polymerase chain reaction
using primers containing relevant restriction sites and
cloned into the pLZRS-vectors. The 5' forward primer
sequences used were ATTGAATTCAGAAGAATG-
GAAACTCTC containing the EcoRI restriction-site for
the TCR AV3S1 chain, CGCGGATCCACCATG-
GTCCTGAAATTCTCCG containing the BamHI re-
striction-site for the TCR AV10S1 chain, TATGGATC-
CCTGCCATGGGCACCAG containing the BamHI
restriction-site for the 3HA15 TCR BV7S9 chain and
TAGAGAATTCCACCATGGGCACCAGTCTCC-
TATGC containing the EcoRI restriction-site for the
5W38 TCR BV7S9 chain. The 3' reverse primer
sequences used were TATCTCGAGATAAATT-
CGGGTAGGATC containing the XhoI restriction-
site for both TCR AV chains, GGTGTCGACTGG-
GATGGTTTTGGAG containing the SalI restriction-
site for the 3HA15 TCR BV7S9 chain and CCG-
GAATTCAGAAATCCTTTCTCTGACC containing
the EcoRI restriction-site for the 5W38 TCR BV7S9
chain (Eurogentec, Seraing, Belgium). The TCR
AV3S1 chain of 3HA15 was cloned into the pLZRS-
dNGF-R vector, while the 3HA15 TCR BV7S9 chain
was cloned into the pLZRS-eGFP vector. The TCR
AV10S1 chain of clone 5W38 was cloned into the
pLZRS-eGFP vector, whereas its TCR BV7S9 chain
was cloned into the pLZRS-dNGF-R vector.
Retroviral vectors encoding eGFP or dNGF-R without
additional inserts were used as control (mock) vec-
tors in the experiments. Control cycle sequencing
was performed after which the constructs were
transfected (0.66 mg/mL) into the amphotropic
phoenix packaging cell line (kindly provided by G.
Nolan, Stanford University School of Medicine,
Stanford, CA, USA) using the calcium phosphate
transfection kit (Life Technologies, Gaithersburg,
MD, USA). The phoenix cells were cultured in
Iscove’s modified Dulbecco’s medium (IMDM) sup-
plemented with 10% fetal calf serum. Two days fol-
lowing transfection, 2 mg/mL puromycin (Clonotech
Laboratories, Palo Alto, CA, USA) was added and 10
to 14 days later 20¥106 cells were plated per 150 cm2
culture flask (Beckton Dickinson, San José, CA, USA)
in fresh medium without puromycin. The following
day the medium was refreshed and 24 hours there-
after retroviral supernatant was harvested, cen-
trifuged, and frozen in aliquots at -70°C.
Retroviral transduction of TCRab deficient Jurkat
cells
Prior to transduction of donor T cells, Jurkat clones
deficient for TCRa (a–/–) or TCRb (b–/–) or for both
chains (ab–/–), clone 3, clone 4, and clone 76 respec-
tively,16 were transduced using the various viral
supernatants according to the procedure described
below. At day three, correct expression of transduced
TCRa and/or -b chains was confirmed by measuring
the TCRab expression by FACS analysis, using
PECy5 conjugated anti-TCRab monoclonal antibody
(Pharmingen, San Diego, CA, USA).
Isolation and retroviral transduction of T cells
derived from adult- or cord blood
Peripheral blood mononuclear cells isolated from
HLA-A2neg adult or cord blood donors were stimulat-
ed with 800 ng/mL phytohemagglutinin and 25
U/mL interleukin-2 (Cetus, Emeryville, CA, USA) in
IMDM containing 10% human serum at a concentra-
tion of 1¥106/mL. After 2 days of culture, T cells were
transduced with retroviral supernatant using recom-
binant CH-296 human fibronectin fragments22
(Retronectin, Takara, Otsu, Japan). Briefly, 0.5¥106 T
cells per well were cultured overnight at 37°C togeth-
er with 0.25 mL TCRa- and 0.25 mL TCRb retroviral
supernatant and 0.5 mL of fresh IMDM containing
10% fetal calf serum and 25 U/mL interleukin-2 in
non-tissue culture treated CH-296-coated 24-well
plates.16 Next, the cells were washed and transferred
to tissue culture treated 24-well plates at a concentra-
tion of 0.5¥106 cells per well in IMDM containing
10% human serum and 25 U/mL interleukin-2.
Flow cytometric analysis and fluorescence-activated
cell sorting
Transduction efficiencies were measured 3-5 days
after transduction by the expression of the markers
eGFP and dNGF-R. T cells positive for both markers
and negative for CD4 were sorted at 1 or 25
cells/well by fluorescence-activated cell sorting
(FACS) using a FACSVantage (Becton Dickinson). PE-
conjugated and PECy5-conjugated antibodies
(Pharmingen) were used to detect dNGF-R expres-
sion and CD4 expression, respectively. FACS sorted
cells were restimulated with randomly selected
peripheral blood mononuclear cells irradiated with
30 Gy, HLA-A2pos/HA-1pos EBV-LCL irradiated with
50 Gy, 25 U/mL interleukin-2 and 800 ng/mL phyto-
hemagglutinin.
Tetramer staining and cytotoxicity assay
Expression of the TCR specific for HLA-A2/HA-1
complexes was measured by staining the cells with
PE-conjugated HLA-A2/HA-1 tetrameric complexes
(HA-1A2), either in combination or not with APC-con-
jugated CD8 antibodies (BD Biosciences, Amster-
dam, The Netherlands). Tetramers were generated
and validated as previously described.7
CTL activity was measured in a chromium release
assay. HLA-A2pos EBV-LCL either positive or negative
for HA-1 were used as target cells. Peripheral blood
or bone marrow containing more than 95% morpho-
logically recognizable malignant cells derived from
HLA-A2pos chronic myeloid leukemia (CML) patients
were used as leukemic target cells. HLA-A2pos fibrob-
lasts derived from a HA-1pos donor were used to test
hematopoietic-restricted specificity of HA-1 TCRab
transduced T cells. Fibroblasts were treated for 24
hours with 250 U/mL interferon-g and tumor necro-
sis factor-a before incubation with effector cells.
Target cells were pulsed with 1 mM HA-1H peptide
(VLHDDLLEA) where indicated. Chromium labeled
target cells were added to various numbers of effec-
tor cells and were cultured for 4 or 18 hours at 37°C.
Supernatant was harvested and measured in a lumi-
nescence counter (Topcount-NXT; Packard, Meriden,
CT, USA). The mean percentage of specific lysis in
triplicate wells was calculated using the following
formula: 
Experimental release – Spontaneous release
Maximal release – Spontaneous release
Results
Cell surface expression of TCRab following retroviral
transduction into Jurkat cells
Retroviral vectors encoding the different TCRa or
b chains derived from HA-1-specific CTL clones
3HA15 or 5W38 were transduced into various Jurkat
cells. The cell surface expression of the transduced
TCRab gene products was analyzed. The TCRa-
deficient Jurkat cells (see Design and Methods) trans-
duced with the HA-1 TCR a chain from either HA-
1-specific CTL clone 3HA15 (Figure 1A) or 5W38
(data not shown) expressed TCRab complexes at the
cell surface. Similarly, the TCRb-deficient Jurkat cells
(see Design and Methods) transduced with the HA-1
TCRab chain from either HA-1 CTL clone 3HA15 or
5W38 expressed TCRab complexes at the cell sur-
face. These data demonstrate that the retrovirally
transduced HA-1 TCRa chains as well as the HA-1
TCRb chains can pair with the endogenous Jurkat
TCR chains, respectively. However, some TCRb–/–
Jurkat cells transduced with HA-1 TCRb chains did
not express the HA-1 TCR or expressed TCR at a low
level. Transduction of both the HA-1 TCRa and -b
chains of the two different HA-1 CTL clones into
TCRab-deficient Jurkat cells resulted in intact HA-1
TCRab cell surface expression (data not shown). Thus,
the individual HA-1 TCR chains pair with each other
and are able to form stable TCR complexes at the cell
surface.
Transduction of the HA-1 TCRab chains into adult
peripheral blood-derived T cells
The TCRa and b chain derived from the HA-1-
specific CTL clones 3HA15 and 5W38 were trans-
duced into peripheral blood mononuclear cells isolat-
ed from various HLA-A2neg adult donors. The trans-
duction efficiency of the HA-1 TCRa chains varied
between 14-23%, whereas the transduction efficien-
cy of the HA-1 TCRb chains varied between 27-
35%. T cells isolated from adult peripheral blood
HA-1 TCR transfer into adult and cord blood T cells
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mononuclear cells that were negative for CD4 and
expressed both marker genes (6-10%) were FACS
sorted and expanded (see Design and Methods).
Despite stable expression of the marker genes eGFP
and dNGFR (data not shown), only low numbers of
HA-1 TCRab transduced adult T cells stained specif-
ically with HA-1A2 tetramers (Figure 1B).
Functional analysis of HA-1 TCRab transduced adult
peripheral blood-derived T cells
The HA-1 TCRab transduced T cells were subse-
quently analyzed for their functional activity and speci-
ficity. The cytolytic activities of 3HA15 TCRab trans-
duced T cells from one representative donor are depict-
ed in Figure 2. The 3HA15 or 5W38 TCRab transduced
T cells specifically lysed HLA-A2pos/HA-1neg EBV-LCL
target pulsed with HA-1 peptide and, importantly, the
natural ligand expressing HLA-A2pos/HA-1pos EBV-LCL
target cells. Compared with the original CTL clone
3HA15 analyzed in parallel, the HA-1 TCRab trans-
duced T cells required a longer incubation time to lyse
target cells expressing HA-1. After 4 hours of incubat-
ing effector and target cells together, HA-1 TCRab
transduced T cells showed specific lysis of target cells
pulsed with HA-1 peptide, but no lysis on the natural
ligand. After 18 hours of incubation, HA-1 TCRab
transduced T cells displayed strong and specific lytic
capacities on both the peptide loaded and the natural
ligand target cells comparable to that of the original
CTL clones. The mock-transduced bulk population did
not lyse any of the target cells. 
Next, we tested the lysis of leukemic targets by
3HA15 or 5W38 TCRab transduced T cells (Figure 3).
Short-term expanded HA-1 TCRab transduced T cells
lysed leukemic cells expressing HA-1, but not HA-1neg
leukemic cells, after 4 hours of incubation. Specific and
much stronger lysis was observed after 18 hours of
Figure 1. Cell surface expression of TCR after transfer of genes
encoding HA-1 TCRa and TCRb chains into Jurkat cells and adult
T cells. TCRa or b deficient Jurkat cells (A) or peripheral blood-
derived adult T cells (B) were transduced with HA-1 TCRa and b
chains from CTL clone 3HA15. Intact TCRab expression is shown
as filled histogram plots. Open histograms represent mock-trans-
duced Jurkat cells positive for the marker gene. HA-1 TCRab or
mock-transduced adult T cells double positive for eGFP and dNGF-
R expression were FACS sorted (indicated by arrow), expanded
and stained with HA-1A2 tetrameric complexes.
A
TCRab
10%
3% 0.6%
6%
19%
14%
27%
Co
un
ts
Co
un
ts
HA-1 TCR
6.6%
mock
eGFP
d-
NG
FR
eGFP
HA
-1
A2
te
tr
am
er
B
Figure 2. Functional analysis of HA-1 transduced adult T cells. The
HA-1-specific cytotoxic activity of HA-1 TCRab transduced T cells
(C,D) and mock-transduced T cells (E,F) after 4 and 18 hours of
incubation is shown. The original CTL clone 3HA15 was tested in
parallel (A,B). Target cells: HA-1neg EBV-LCL (open dots), HA-1neg
EBV-LCL pulsed with HA-1 peptide (filled squares) and HA-1pos EBV-
LCL (filled triangles).
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incubation. Similar results were obtained when HA-1-
expressing EBV-LCL target cells were used (data not
shown). In line with the results on bulk HA-1 TCRab
transduced T cells, short-term expanded HA-1 TCRab
transduced T cells stained low but specifically with
HA-1A2 tetramers.
Transduction of the HA-1 TCR TCRab chains into cord
blood-derived T cells
The TCRa and b chains derived from the HA-1 spe-
cific CTL clone 3HA15 were transduced into peripher-
al blood mononuclear cells isolated from various HLA-
A2neg cord blood donors. The transduction efficiencies
of both the TCRa and the TCRb chains were in the
same range as observed for the peripheral blood
mononuclear cells  from adults (15-40%). HA-1 TCRab
transduced cord blood-derived T cells (4-20%) were
FACS sorted (depleted for CD4+ T cells) and expanded.
HA-1 TCRab transduced cord blood T cells displayed
low HA-1A2 tetramer staining comparable to that of the
HA-1 TCRab transduced adult T cells described above
(data not shown).
Figure 3. Recognition patterns of HA-1 TCRab
transduced adult T cells against leukemic cells.
HA-1-specific lysis of two representative HA-1
TCRab transduced T-cell clones was measured
after 4 or 18 hours of effector/target cell incuba-
tion at an E:T ratio of 10:1. The original HA-1-spe-
cific CTL clones 3HA15 and 5W38 were analyzed
in parallel. The horizontal lines in the left figures
represent the background lysis by mock-trans-
duced T cells tested in parallel. Target cells: HA-1pos
chronic myeloid leukemia cells (CML, filled bars),
HA-1neg CML cells (open bars). Corresponding HA-
1A2 tetramer staining of the 3HA15 and 5W38 HA-
1 TCRab transduced T-cell clones is shown.
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Figure 4. Functional analysis of HA-1 TCRab trans-
duced cord blood T cells. A. HA-1 specific lysis by
HA-1 TCRab transduced cord blood T cells and by
mock-transduced cord blood T cells after 18 hours
of incubation is shown. The original HA-1-specific
CTL clone 3HA15 was tested in parallel. Target
cells: HA-1neg EBV-LCL (open dots), HA-1neg EBV-LCL
pulsed with HA-1 peptide (filled squares), HA-1pos
EBV-LCL (filled triangles), HA-1neg CML cells (open
diamonds) and HA-1pos CML cells (asterisks). B.
Hematopoietic-restricted lysis by HA-1 TCRab
transduced cord blood T cells after 4 and 18 hours
of effector/target cell incubation is shown. A con-
trol allo HLA-A2-specific CTL clone was tested in
parallel. Target cells: fibroblasts (filled squares)
and fibroblasts pulsed with HA-1 peptide (open
squares). The fibroblasts were derived from an
HLA-A2pos/HA-1pos donor. 
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Functional analysis of HA-1 TCRab transduced cord
blood-derived T cells
The HA-1 TCRab transduced cord blood T cells were
subsequently analyzed for their hematopoietic-specific
lytic capacities (Figure 4). HA-1 TCRab transduced
cord blood T cells lysed HLA-A2pos/HA-1pos leukemic
cells and EBV-LCL target cells that were either pulsed
with HA-1 peptide or naturally expressed HA-1. Similar
to the results obtained with the HA-1 TCRab trans-
duced adult T cells, specific and strong lysis of target
cells expressing HA-1 required prolonged incubation of
effector and target cells. The original HA-1-specific
CTL clone 3HA15 and the mock-transduced T cells
were analyzed in parallel. Mock-transduced T cells did
not lyse any of the target cells.
Besides the recognition of the relevant EBV-LCL and
leukemia cells, the HA-1 TCRab transduced cord blood
T cells were analyzed for their hematopoietic-restricted
specificity (Figure 4B). HA-1 TCRab transduced cord
blood T cells did not lyse fibroblasts derived from an
HLA-A2pos/HA-1pos donor, whereas these target cells
were recognized by an allo HLA-A2-specific T-cell
clone tested in parallel. The same fibroblasts pulsed
with HA-1 peptide were efficiently lysed by HA-1
TCRab transduced cord blood T cells. Herewith, the
recognition pattern of the HA-1 TCRab transduced
cord blood T cells is indicated to be restricted to cells
specific to the hematopoietic system. 
Collectively, these results show that HA-1 TCRab
transfer into HLA-A2neg adult or into HLA-A2neg cord
blood T cells results in functional cytotoxic T cells that
display specific reactivity against HLA-A2pos HA-1-
expressing target cells including leukemic cells.
Discussion
We studied the feasibility of transferring the genes
encoding HA-1 TCRa and b chains into HLA-A2neg
adult and into HLA-A2neg cord blood T cells and ana-
lyzed the HA-1 TCRab transduced T cells for their anti-
gen-specific lytic potential. We showed that these HA-
1 TCRab transduced HLA-A2neg adult and cord blood T
cells can indeed acquire HA-1 specific and lytic activity.
The feasibility of transferring functional HA-1 TCRab
encoding genes into HA-1 TCR negative cells lays the
basis for a potential broad spectrum of applications in
stem cell based immunotherapy of hematologic malig-
nancies and solid tumors. It is worthwhile mentioning
that besides the hematopoietic-restricted specificity,
HA-1 is also expressed on epithelial cancer cells.
Moreover, our results set the stage for broadening the
use of the immunodominant and hematopoietic-specif-
ic mHag HA-1 to the setting of HLA-mismatched SCT.
It should be noted however that although the specific
functional activity of the HA-1 TCR can indeed be
transferred, significant improvements in transduction
efficiency, HA-1 TCR avidity for its ligand and relevant
expansion of HA-1 TCR TCRab transduced T cells
need to be established before HA-1 TCR transduced T
cells can be therapeutically applied.
Endogenous TCR, transduced TCR and hybrid TCR
possibly compete for CD3 association and therewith
for functional cell surface expression.23 This feature may
explain the lack of correlation between the intensity of
double marker expression and the cell surface expres-
sion, as measured by HLA-A2/HA-1-specific tetramers,
of stable HA-1-specific TCR complexes following
transduction. The presence of other TCR on the cell
surface may also hamper HA-1 TCR clustering, lipid
raft formation24,25 and rapid activation upon antigen
encounter. Moreover, the granzyme depot and thus the
intrinsic cytolytic capacity of the TCR-transduced T
cells may be inferior to that of the non-transduced CTL
clones. We also noticed that HA-1 TCRab transduced
T cells generally require more time than the original
non-transduced HA-1-specific CTL clones to lyse their
target cells. We encountered the same phenomenon of
low tetramer staining and slow but antigen-specific lysis
in our earlier study using HA-2-specific TCR transfer.16
A single chain construct containing both the TCRa and
b chains combined with strategies that can prevent the
formation of hybrid TCR or suppress endogenous TCR
expression23 is necessary to improve functional HA-1
TCR transfer. Improved gene expression may be
obtained with more effective retroviral vector systems26
or a lentiviral-based transduction procedure. Hybrid
pairing of the different TCRa and b chains following
retroviral transduction may also result in the formation
of new TCR of unknown specificities.23 It is clear that
the above mentioned, as yet unsolved, processes need
extensive additional analyses before in vivo transfer
with TCR-transduced T cells can be executed. Serious
attention should be focused on the potential risks of
graft-versus-host-disease as well as undesired autoim-
mune reactions that may occur upon adoptive transfer
of TCR-modified T cells. Suicide gene control of the ex-
vivo HA-1 TCRab transduced T cells may be included
to potentially control undesired alloreactivity.27,28
HA-1 TCRab transfer may be of special use in the
setting of CBT. Currently, a treatment for hematologic
malignancies that relapse after CBT is lacking. Cord
blood is obtained anonymously and contains far too
few lymphocytes for the purpose of DLI. CBT is usual-
ly performed with 1-2 HLA-mismatched grafts.29 HLA
disparity is not, however, significantly associated with
a higher risk of graft-versus-host-disease in this trans-
plantation modality. HA-1-specific TCRab transfer into
cryopreserved HLA-A2neg cord blood T cells may be a
strategy requiring low numbers of donor cells for
immunotherapeutic purposes for HLA-A2 positive
patients. A universal option would be to generate pre-
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fabricated HA-1 TCRab transduced T cells derived from
HLA-A2neg cord blood donors who have frequent HLA-
homozygous haplotypes. HLA-A2pos patients who
match the remaining HLA type of the cord blood
donor can be treated with these off the shelf HA-1
TCRab transduced T cells. 
In summary, our results provide the proof of principle
that transfer of HA-1 specificity into HA-1 TCR nega-
tive cells is feasible. Current studies focus on the gener-
ation of sufficient numbers of HA-1 TCRab transduced
cord blood T cells with high ex vivo expansion potential
and lytic capacity. 
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